CN111298118A - Mapk14抑制剂在制备药物中的应用 - Google Patents
Mapk14抑制剂在制备药物中的应用 Download PDFInfo
- Publication number
- CN111298118A CN111298118A CN202010085986.2A CN202010085986A CN111298118A CN 111298118 A CN111298118 A CN 111298118A CN 202010085986 A CN202010085986 A CN 202010085986A CN 111298118 A CN111298118 A CN 111298118A
- Authority
- CN
- China
- Prior art keywords
- mapk14
- prolactin
- pituitary
- prl
- adenoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150003941 Mapk14 gene Proteins 0.000 title claims abstract description 117
- 108700012928 MAPK14 Proteins 0.000 title claims abstract description 86
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 title claims abstract description 82
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 title claims abstract description 82
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 title claims abstract description 82
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title description 9
- 108010057464 Prolactin Proteins 0.000 claims abstract description 148
- 102000003946 Prolactin Human genes 0.000 claims abstract description 148
- 229940097325 prolactin Drugs 0.000 claims abstract description 148
- 208000003200 Adenoma Diseases 0.000 claims abstract description 103
- 206010001233 Adenoma benign Diseases 0.000 claims abstract description 86
- 230000014509 gene expression Effects 0.000 claims abstract description 64
- 230000001817 pituitary effect Effects 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 230000028327 secretion Effects 0.000 claims abstract description 17
- 230000012010 growth Effects 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 239000003550 marker Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 25
- 108020004459 Small interfering RNA Proteins 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 230000002452 interceptive effect Effects 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000010362 genome editing Methods 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- -1 small molecule compounds Chemical class 0.000 claims description 3
- 230000008045 co-localization Effects 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 25
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 14
- 206010062767 Hypophysitis Diseases 0.000 description 12
- 210000003635 pituitary gland Anatomy 0.000 description 12
- 238000011529 RT qPCR Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 10
- 101150008197 PRL gene Proteins 0.000 description 9
- 208000010916 pituitary tumor Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 5
- 229960002802 bromocriptine Drugs 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 description 2
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 208000014993 Pituitary disease Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229960000924 quinagolide Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000687471 Mus musculus Prolactin Proteins 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 206010068268 Tumour compression Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000008195 breast development Effects 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 210000000711 cavernous sinus Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001756 lactotroph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960001511 pergolide mesylate Drugs 0.000 description 1
- UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010085986.2A CN111298118B (zh) | 2020-02-11 | 2020-02-11 | Mapk14抑制剂在制备药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010085986.2A CN111298118B (zh) | 2020-02-11 | 2020-02-11 | Mapk14抑制剂在制备药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111298118A true CN111298118A (zh) | 2020-06-19 |
CN111298118B CN111298118B (zh) | 2022-03-22 |
Family
ID=71145167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010085986.2A Active CN111298118B (zh) | 2020-02-11 | 2020-02-11 | Mapk14抑制剂在制备药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111298118B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317612A (zh) * | 2022-07-29 | 2022-11-11 | 中南大学 | 高表达热休克蛋白的巨噬细胞作为靶点在制备肝细胞癌药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151742A (zh) * | 2019-05-22 | 2019-08-23 | 王雄 | 大麦芽碱在制备治疗垂体瘤药物中的用途 |
CN110275010A (zh) * | 2019-06-21 | 2019-09-24 | 中山大学孙逸仙纪念医院 | 一种用于治疗前列腺癌药物的P38a MAPK信号通路抑制剂的筛选方法 |
-
2020
- 2020-02-11 CN CN202010085986.2A patent/CN111298118B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151742A (zh) * | 2019-05-22 | 2019-08-23 | 王雄 | 大麦芽碱在制备治疗垂体瘤药物中的用途 |
CN110275010A (zh) * | 2019-06-21 | 2019-09-24 | 中山大学孙逸仙纪念医院 | 一种用于治疗前列腺癌药物的P38a MAPK信号通路抑制剂的筛选方法 |
Non-Patent Citations (4)
Title |
---|
DING ET AL.: "Inhibiting MAPK14 showed anti-prolactinoma effect", 《BMC ENDOCRINE DISORDERS》 * |
HARUHIKO KANASAKI等: "Involvement of p38 Mitogen-Activated Protein Kinase Activation in Bromocriptine-Induced Apoptosis in Rat Pituitary GH3 Cells", 《BIOLOGY OF REPRODUCTION》 * |
MIAOLONG LU ET AL.: "The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas", 《FRONTIERS IN ENDOCRINOLOGY》 * |
XIONG WANG ET AL.: "Antiprolactinoma Effect of Hordenine by Inhibiting MAPK Signaling Pathway Activation in Rats", 《HINDAWI》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317612A (zh) * | 2022-07-29 | 2022-11-11 | 中南大学 | 高表达热休克蛋白的巨噬细胞作为靶点在制备肝细胞癌药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111298118B (zh) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | H3 K27M–mutant diffuse midline gliomas in different anatomical locations | |
US6110672A (en) | Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof | |
US20110306654A1 (en) | Methods for identifying analgesic agents | |
CN101608240A (zh) | 用于检测人类egfr基因突变的引物、探针及其使用方法 | |
CN107109494A (zh) | Il‑33介导型疾病的治疗方法和诊断方法 | |
CN105002283B (zh) | 一种用于检测人c-kit基因突变的QPCR组合物及试剂盒 | |
CN105838777A (zh) | ddPCR技术监测肺癌患者对酪氨酸激酶抑制剂继发耐药的方法 | |
JP4201057B2 (ja) | ヒト転移サプレッサー遺伝子kaiiに由来する試薬を使用する診断方法及び遺伝子療法 | |
CN111298118B (zh) | Mapk14抑制剂在制备药物中的应用 | |
CN110244056B (zh) | Znf521基因在制备肝癌治疗药物、诊断及预后评估试剂中的应用 | |
CN100564524C (zh) | 新转移因子及其应用 | |
CN111187835A (zh) | 胰腺癌的靶点erbb2及其在诊断和治疗中的应用 | |
JP6831112B2 (ja) | Pd−1経路阻害薬の著効例を予測するためのバイオマーカー | |
CA2991076A1 (en) | Methods for identification, assessment, prevention, and treatment of metabolic disorders using slit2 | |
KR102574799B1 (ko) | 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트 | |
KR102331240B1 (ko) | Sgk3 유전자를 이용한 뇌신경계 질환의 진단 및 치료 | |
AU606946B2 (en) | Diagnosing obesity caused by a genetic abnormality and method of therapeutically treating genetically caused obesity | |
AU763574B2 (en) | Human vault RNA | |
CN105838779A (zh) | ddPCR技术监控胃肠道间质瘤患者对伊马替尼/舒尼替尼耐药的方法 | |
CN105838781A (zh) | ddPCR技术监测伊马替尼(格列卫)/尼罗替尼继发耐药的方法 | |
CN109136369A (zh) | 一种egfrt790m稀有突变高灵敏免提取检测试剂盒 | |
CN107151699A (zh) | 检测nup214‑abl1基因相对表达量的试剂盒和方法 | |
US20130156793A1 (en) | Insulin-resistance-improving drug | |
KR102549771B1 (ko) | 대장암 전이 억제제 스크리닝 방법 | |
KR102202120B1 (ko) | 알츠하이머 질환의 진단 또는 치료를 위한 Ube2h의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220321 Address after: 430000 No. 1, Huangjiahu Huanhu West Road, Qingling Township, Hongshan District, Wuhan City, Hubei Province Patentee after: Wang Xiong Patentee after: Wuhan Yefeng Biotechnology Co.,Ltd. Address before: 430000 No. 1, Huangjiahu Huanhu West Road, Qingling Township, Hongshan District, Wuhan City, Hubei Province Patentee before: Wang Xiong Patentee before: WUHAN THIRD Hospital |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240322 Address after: No. 241, pengliuyang Road, Wuchang District, Wuhan City, Hubei Province 430000 Patentee after: WUHAN THIRD Hospital Country or region after: China Address before: 430000 No. 1, Huangjiahu Huanhu West Road, Qingling Township, Hongshan District, Wuhan City, Hubei Province Patentee before: Wang Xiong Country or region before: China Patentee before: Wuhan Yefeng Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |